Growth inhibition and cytotoxicity induced by Bowman-Birk inhibitor concentrate in cisplatin-resistant human ovarian cancer cells.
Bowman-Birk inhibitor (BBI) is a soybean-derived anticarcinogenic protease inhibitor that was shown to potentiate the cytotoxicity of cisplatin in our previous studies. To assess the potential of BBI as a sensitizing agent for the chemotherapy of cisplatin-resistant cancers, we evaluated the effects of a soybean concentrate enriched in BBI (known as BBI concentrate or BBIC) on cell growth and clonogenic survival of a human ovarian cancer cell line, A2780, and its cisplatin-resistant sublines, C30, and C200. The presence of BBI and BBIC in the cell culture, medium reduced the clonogenic survival of the A2780, C30, and C200 cells in a dose-dependent manner and enhanced cisplatin-induced growth inhibition and/or cytotoxicity. BBIC alone showed greater inhibitory effects on growth in the cisplatin-resistant cell lines. These results suggest that BBI and BBIC could be useful agents for the treatment of cancers, especially with cisplatin, in tumors resistant to this important anticancer agent.
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.
X S
XS
Wan
T C
TC
Hamilton
J H
JH
Ware
J J
JJ
Donahue
A R
AR
Kennedy
D016923:Cell Death; D002455:Cell Division / Q000187:drug effects*; D002470:Cell Survival; D002945:Cisplatin / Q000494:pharmacology*; D003470:Culture Media; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000473:pathology*; D014358:Trypsin Inhibitor, Bowman-Birk Soybean / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D003470:Culture Media; D014358:Trypsin Inhibitor, Bowman-Birk Soybean; D002945:Cisplatin